Who
Samuel J. Reich
CEO
Company insider
Files Form 4 as: CEO, SAB Biotherapeutics; Executive VP, Opko Health.
In numbers
- Trades disclosed
- 25
- Buys
- 3
- Sells
- 0
- Bought
- $4.2M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 29 Mar 2007
- Last trade
- 3 Feb 2026
- Last filed
- 5 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,800,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,800,000 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,800,000 at $0.00 | filing |
| 15 Jul 2024filed 17 Jul 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —434,000 at $0.00 | filing |
| 29 Nov 2023filed 30 Nov 2023 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $9,79011,000 at $0.89 | filing |
| 14 Mar 2023filed 16 Mar 2023 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 28 Feb 2023filed 2 Mar 2023 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —208,600 at $0.00 | filing |
| 28 Feb 2023filed 2 Mar 2023 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —9,968 at $0.00 | filing |
| 13 Sep 2022filed 15 Sep 2022 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 20 May 2022filed 23 May 2022 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code J | —2,500,127 at $0.00 | filing |
| 20 May 2022filed 23 May 2022 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Code J | —207,001 at $0.00 | filing |
| 16 Mar 2022filed 18 Mar 2022 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | SABS SAB Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 14 Oct 2021filed 15 Oct 2021 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $10K1,000 at $10.11 | filing |
| 14 Jan 2021filed 14 Jan 2021 | SABS SAB BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $4.2M417,200 at $10.00 | filing |
| 29 Mar 2007filed 2 Apr 2007 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code J | —14,883 at $0.00 | filing |
| 29 Mar 2007filed 2 Apr 2007 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code J | —14,883 at $0.00 | filing |
| 29 Mar 2007filed 2 Apr 2007 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code J | —14,883 at $0.00 | filing |
| 29 Mar 2007filed 2 Apr 2007 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code J | —259,471 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.